BPIQ Pro Investor Posts

Private bio/pharma funding activity rose sharply in Q3 2026 after a difficult first half. BiopharmIQ recorded approximately $15.33B across 365 funding events covering 349 companies. Both event counts and funding amounts exceeded Q2 2026 and Q3 2024 and 2025. Early-stage funding also improved from Q3 2025, although amounts remained below Q3 2024. Large debt and refinancing transactions contributed significantly to the overall funding total. Please note: In this report, funding

Bio/pharma IPO activity increased in Q3 2026, with BPIQ recording 10 priced offerings, compared with seven in Q1 and eight in Q2. July brought three listings, August five, and September two. That puts 2026 at 25 IPOs through September, already above the full-year total for each year from 2022 through 2025. The Quarterly View Q3 was the busiest quarter since 2021 in BPIQ’s dataset. Still, its 10 IPOs were well below the 25 recorded in Q3 2021. Activity is recovering, but the m

We've been working with BPIQ AI to provide more information about upcoming catalysts for investors to consider in their diligence of smid-cap biopharma companies. The table below shows BPIQ AI's predicted probabilities (FN1) that each of 20 October and November 2026 Phase 2 and Phase 3 readouts, across 16 companies, will read out as a clean positive, a clean negative, or with mixed data, along with its predicted stock move for each outcome. Keep in mind that predicting cataly

Our September Pro pick is VRDN. With Lumvoa approved and positive follow-on Phase 3 results, attention turns to its TED launch and planned Q1 2027 filing. Read the full VRDN report.

Explore BPIQ-AI forecasts for September 2026 Phase 2 and Phase 3 readouts, including Clean+, Mixed, and Clean− probabilities, expected stock move ranges, and insights from live options data.

Summary

Explore BPIQ’s August 2026 biopharma hedge fund stock picks, $MIRM and 2 more with key regulatory, Phase 3 readout, and pipeline catalysts ahead.

Q2 earnings reports are arriving quickly, with several notable Bio/Pharma companies scheduled to report between August 5 and August 12. For this earnings watchlist, BPIQ evaluated its model-portfolio positions, tracked hedge-fund participation, financial indicators, commercial performance and upcoming clinical and regulatory catalysts. The strongest concentration of signals is found in CYTK, RVMD, MIRM, XENE and CMPS. Five additional companies complete BPIQ’s Top 10, ad

Explore hedge fund positions and BPIQ model-portfolio overlap in Terns, Centessa, and RAPT before their 2026 biotech M&A deals.

Explore BPIQ’s July 2026 biopharma hedge fund stock picks, COGT, IRON, and TENX, and the key regulatory, Phase 3, and pipeline catalysts ahead.

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

BPIQ has released its H2 2026 Big Movers list, highlighting biotech catalysts with the greatest potential to drive meaningful stock moves. The list includes 18 Big Movers and 79 Suspected Movers. Suspected Movers are catalysts BPIQ identifies as having significant stock-move potential. Big Movers are near-term Suspected Movers where options-implied volatility confirms that the market is pricing in a large move. Elite and APEX subscribers can also see whether a Big Mover is de

Summary

BPIQ’s June 2026 Hedge Fund Stock Picks highlight three biopharma names with different catalyst profiles. This Pro version features the full CLDX pick, including its later-stage immunology setup, pivotal data ahead, and downloadable PDF report.

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms. From BPIQ’s lens, several technology themes stood out. ADCs Stayed at the Center of Oncology Antibody-drug conjugates remained one of the most active modalities across the meeting. Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Th

ASCO 2026 delivered important updates across hematologic malignancies, lung cancer, breast cancer, gastrointestinal cancers, melanoma, and several rare and difficult-to-treat tumors. Across the meeting, ADCs, bispecific antibodies, cell therapies, radioligand approaches, and increasingly precise biomarker-driven strategies remained at the center of oncology innovation. One presentation stood above the rest. During the Day 3 Plenary Session, Revolution Medicines presented what

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Background After extensive back-testing to find to identify the best strategies for using consensus holdings of top institutional investors to consistently beat the biotech benchmarks, we launched our first consensus-based portfolio (Top 20s) on 4/1/2023. By 9/30/2023, we applied the hedge fund favo

Day 2 of ASCO 2026 shifted the spotlight from ADC-heavy discussions toward cell therapy, precision oncology, and several important late-stage studies. While major pharmaceutical companies continued to present updates from established programs, some of the most interesting stories came from companies advancing TCR-T therapies, next-generation targeted treatments, and novel immunotherapy approaches. Here are five tickers that stood out: IMTX: TCR-T Therapy Continues Its Push in

ASCO is one of the most important events on the biotech calendar, but not every presentation captures investors' attention equally. Day 1 featured dozens of clinical updates across oncology, yet a handful of companies stood out because of the technologies they are advancing, the markets they are targeting, and the potential impact on future valuations. Here are five tickers that mattered on Day 1 of ASCO 2026. NUVL: Building a Potential Next-Generation ALK Franchise Nuvalent